Ohio State Wexner Enrolls First Midwest Patient in Trial
The clinical trial evaluates a novel catheter system designed to treat recurrent ventricular tachycardia.
Updated on Oct. 29, 2026 in Heart Disease
Live Poll
Do you believe new medical device trials generally lead to better health outcomes for patients?
Ohio State Wexner Medical Center has enrolled the first patient in the Midwest for a clinical trial testing a new device for recurrent ventricular tachycardia. The investigational catheter performs heart mapping, treatment, and rhythm verification without requiring device exchanges.
Why it matters
Recurrent ventricular tachycardia is a life-threatening condition, and the development of more efficient, effective tools is critical for patient survival. The trial aims to address the need for advanced treatment options by combining mapping and ablation capabilities in one system.
The Sphere-9 catheter allows for both radiofrequency and non-thermal pulsed electric field energy usage. The FDA granted breakthrough device designation to this investigational technology in April 2026.
The players
Ohio State Wexner Medical Center
This is a prominent academic medical center located in Columbus that serves as a research hub for advanced cardiac care.
Medtronic
This medical device company manufactures the mapping system and catheter used in this clinical trial.
The details
Electrophysiologists use a Medtronic-manufactured system to destroy abnormal heart tissue responsible for the arrhythmia. By integrating mapping and rhythm checking into a single catheter, the procedure aims to improve the efficiency of heart rhythm treatments.
Timeline
2020: Ohio State first used pulsed field ablation technology.
April 2026: FDA granted breakthrough device designation.
October 16, 2026: Ohio State physician performed the procedure.
October 28, 2026: Trial enrollment at Ohio State reported.
Health Landscape
The trial follows the precedent set by the FDA breakthrough device designation program to expedite development for life-threatening conditions. This marks a continued shift toward integrating advanced energy systems into minimally invasive cardiac procedures.
The use of an all-in-one catheter could eventually reduce the time patients spend under anesthesia by eliminating the need for device exchanges during procedures. This trial represents a step toward more efficient treatment options for individuals suffering from recurrent ventricular tachycardia.
The takeaway
This trial underscores the rapid evolution of electrophysiology tools that allow for more precise destruction of abnormal heart tissue. Patients with chronic arrhythmias may see improved procedure outcomes as these integrated technologies move through regulatory review.
Further reading
Learn more about advancements in Heart Disease management and research.
Source note: This article includes information reported by News-Medical.
Live Poll
Do you believe new medical device trials generally lead to better health outcomes for patients?
